Loading...
•
Mar 31, 2020
Marinus Pharmaceuticals Q1 2020 Earnings Report
Marinus Pharmaceuticals reported first quarter 2020 financial results and provided business update.
Key Takeaways
Marinus Pharmaceuticals reported a net loss of $18.7 million for the first quarter of 2020, compared to a net loss of $12.5 million for the same period in 2019. The company's cash and cash equivalents totaled $77.8 million as of March 31, 2020.
Constructive end of Phase 2 meeting with FDA for Status Epilepticus was completed in March.
Pivotal Phase 3 clinical trial for Status Epilepticus is expected to begin next quarter.
Topline data is on track for Q3 2020 from Pivotal Phase 3 Marigold Study in CDKL5 Deficiency Disorder.
First patients to be screened this quarter for Phase 2 Tuberous Sclerosis Complex Clinical Trial.
Forward Guidance
Marinus believes that its cash, cash equivalents and investments as of March 31, 2020 will enable the Company to fund operating expenses and capital expenditure requirements into the third quarter of 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...